Challenging quarter across key segments

Company
12 Aug 2024
5 Min read 
  • Biocon's financials and valuations are detailed for FY24, FY25E, and FY26E.
  •  The company's sales, EBITDA, adjusted PAT, and margins are provided.
  •  The shareholding pattern, CMP, and TP are mentioned.
  •  The company's performance in 1QFY25 is discussed, including sales, margins, and EBITDA.
  •  The management's commentary and future outlook for the company are highlighted.
  •  The valuation and view of the company are reiterated as neutral.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority

Click here to see your activities